---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055667"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:46:18.089316+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Surrozen Q1 net loss $8.8M; cash $27.3M; SZN-043 Phase 1b enrollment starts Q2 2024

## Summary
- Cash $27.3M at Mar 31; proforma $43.2M after April financing. Net loss $8.8M vs $14.3M YoY.
- R&D expense $5.2M (down 36% YoY); G&A $3.9M (down 26% YoY) reflecting 2023 restructuring.
- SZN-043 Phase 1a completed; Phase 1b enrollment to begin Q2 2024; proof-of-concept data expected H1 2025.
- Potential $10M milestone from Boehringer Ingelheim if lead Fzd-4 Wnt agonist candidate nominated in 2024.
- Preclinical data at ARVO on Wnt mimetic for corneal dystrophies; publication on pulmonary fibrosis in Respiratory Research.

## SEC filing metadata
- accession: 0000950170-24-055667
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017024055667/0000950170-24-055667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017024055667/srzn-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055667
- JSON: https://secwatch.observer/filing/0000950170-24-055667.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055667.txt

## Key facts
- Earnings Releases
  Surrozen, Inc./DE reported the quarter ended March 31, 2024 results: net income $8.8 million.
  - Period: the quarter ended March 31, 2024
  - Net income: $8.8 million
  - Result: reported results
  source text: Net loss for the first quarter ended March 31, 2024 was $8.8 million, as compared to $14.3 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824893/000095017024055667/0000950170-24-055667-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.